Fundamentals-based quality & risk · not a recommendation
Syncom Formulations (India) Ltd scores 70/100 (Quality) on the Orion Score — moderate business quality (55), strong growth (94), strong balance-sheet safety (82) and cheap valuation (66). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
45/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q3 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹115.14 | ₹18.91 | 17.2% | ₹0.23 |
| Q2 2026 | ₹121.72 | ₹16.6 | 14.0% | ₹0.18 |
| Q1 2026 | ₹116.9 | ₹15.75 | 12.4% | ₹0.21 |
| Q4 2025 | ₹141.24 | ₹17.69 | 15.3% | — |
| Q3 2025 | ₹127.53 | ₹13 | 10.5% | ₹0.14 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹457.37 | ₹49.43 | ₹71.42 | 11.8% |
| FY 2024 | ₹259.24 | ₹25.31 | ₹43.03 | 9.7% |
| FY 2023 | ₹222.49 | ₹20.07 | ₹34.3 | 7.4% |
| FY 2022 | ₹217.82 | ₹19.79 | ₹31.95 | 7.9% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| SYNCOMF ★ | ₹1,362 Cr | 17.89 | 15.30% | 20.19% | 0.00x | 17.24% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹413.28 | ₹404.66 | ₹377.83 | ₹308.24 |
| Equity | ₹342.16 | ₹288.14 | ₹256.01 | ₹222.22 |
| Total Debt | ₹4.58 | ₹72.49 | ₹83.18 | ₹57.79 |
| Cash | ₹0.66 | ₹63.29 | ₹0.76 | ₹0.22 |
| Net Debt | ₹3.93 | ₹9.19 | ₹82.42 | ₹57.57 |
| Working Capital | ₹210.66 | ₹168.26 | ₹68.53 | ₹61.54 |
Q3 FY2026
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q3 FY2026 | 50.57% | 0.26% ↑ | — | 49.17% ↓ |
| Q2 FY2026 | 50.57% | 0.1% ↓ | — | 49.33% ↑ |
| Q1 FY2026 | 50.57% | 0.41% ↑ | — | 49.02% ↓ |
| Q4 FY2025 | 50.57% | 0.11% ↓ | — | 49.32% ↑ |
| Q3 FY2025 | 50.57% | 0.13% ↑ | — | 49.3% ↓ |
| Q2 FY2025 | 50.57% | 0.1% ↑ | — | 49.34% |
| Q1 FY2025 | 50.57% | 0.09% | — | 49.34% |
| Q4 FY2024 | 50.57% | 0.08% | — | 49.35% |
No recent corporate actions
1 mutual fund schemes
Ask: "Is Syncom Formulations (India) Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Syncom Formulations (India) Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE312C01025. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.